安图生物
(603658)
| 流通市值：231.48亿 | | | 总市值：231.48亿 |
| 流通股本：5.71亿 | | | 总股本：5.71亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,060,307,179.95 | 995,933,663.32 | 4,471,202,509.22 | 3,380,035,059.48 |
| 营业收入 | 2,060,307,179.95 | 995,933,663.32 | 4,471,202,509.22 | 3,380,035,059.48 |
| 二、营业总成本 | 1,506,453,270.45 | 746,443,403.96 | 3,307,150,305.92 | 2,408,355,902.26 |
| 营业成本 | 732,834,381.85 | 347,853,931.15 | 1,546,573,971.03 | 1,153,825,249.86 |
| 税金及附加 | 27,676,624.21 | 11,685,533.86 | 48,316,292.22 | 35,859,085.1 |
| 销售费用 | 389,039,334.86 | 195,260,976.79 | 767,766,504.11 | 551,539,143.37 |
| 管理费用 | 102,288,423.93 | 58,570,851.1 | 210,881,373.71 | 148,095,505.61 |
| 研发费用 | 250,345,849.36 | 130,563,085.75 | 731,932,785.27 | 511,265,272.32 |
| 财务费用 | 4,268,656.24 | 2,509,025.31 | 1,679,379.58 | 7,771,646 |
| 其中:利息费用 | 9,517,542.81 | 5,583,446.15 | 22,281,972.04 | 16,950,785.02 |
| 其中:利息收入 | 2,480,460.15 | 1,017,384.07 | 20,565,513.62 | 10,878,628.18 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -54,112.42 | 649,979.05 | 3,609,780.75 | 10,703,146.14 |
| 加:投资收益 | 67,250,439.05 | 23,449,847.26 | 92,272,195.9 | 58,946,984.29 |
| 资产处置收益 | 38,609.84 | 37,110.02 | -1,169,696.21 | -1,168,868.83 |
| 资产减值损失(新) | -14,215,837.01 | 402,957.8 | -62,954,217.56 | -7,026,352.72 |
| 信用减值损失(新) | 1,913,032 | 9,988,165.74 | -55,606,118.47 | -34,952,874.19 |
| 其他收益 | 28,025,398.61 | 19,480,632.72 | 105,284,799.74 | 65,920,794.8 |
| 四、营业利润 | 636,811,439.57 | 303,498,951.95 | 1,245,488,947.45 | 1,064,101,986.71 |
| 加:营业外收入 | 9,879,032.7 | 1,264,348.54 | 62,790,815.15 | 4,151,257.69 |
| 减:营业外支出 | 7,845,037.1 | 2,624,860.36 | 19,223,288.41 | 13,977,192.9 |
| 五、利润总额 | 638,845,435.17 | 302,138,440.13 | 1,289,056,474.19 | 1,054,276,051.5 |
| 减:所得税费用 | 60,808,445.42 | 29,058,717.66 | 89,823,194.3 | 84,843,418.23 |
| 六、净利润 | 578,036,989.75 | 273,079,722.47 | 1,199,233,279.89 | 969,432,633.28 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 578,036,989.75 | 273,079,722.47 | 1,199,233,279.89 | 969,432,633.28 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 571,001,185.83 | 269,880,235.57 | 1,194,451,909.72 | 956,174,546.82 |
| 少数股东损益 | 7,035,803.92 | 3,199,486.9 | 4,781,370.17 | 13,258,086.46 |
| 扣除非经常损益后的净利润 | 546,316,646.83 | 256,895,204.32 | 1,098,820,497.48 | 930,499,370.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.02 | 0.47 | 2.07 | 1.65 |
| (二)稀释每股收益 | 1.02 | 0.47 | 2.07 | 1.65 |
| 八、其他综合收益 | -8,422.01 | -12,112 | 106,410.67 | -138,346.28 |
| 归属于母公司股东的其他综合收益 | -8,422.01 | -12,112 | 106,410.67 | -138,346.28 |
| 九、综合收益总额 | 578,028,567.74 | 273,067,610.47 | 1,199,339,690.56 | 969,294,287 |
| 归属于母公司股东的综合收益总额 | 570,992,763.82 | 269,868,123.57 | 1,194,558,320.39 | 956,036,200.54 |
| 归属于少数股东的综合收益总额 | 7,035,803.92 | 3,199,486.9 | 4,781,370.17 | 13,258,086.46 |
| 公告日期 | 2025-08-22 | 2025-04-18 | 2025-04-18 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |